Medartis Holding AG/Fr. MED
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Medartis Holding AG
Medartis Holding AG is a Swiss company operating in the medical technology industry, primarily focused on the development, manufacturing, and distribution of orthopedic surgical implants. The company's core products include precision implant systems for surgical fixation of bone fractures and osteotomies, particularly in the areas of the head, hand, wrist, foot, and ankle. Founded in 1997 and headquartered in Basel, Switzerland, Medartis has established a presence in key international markets across Europe, the Americas, and Asia-Pacific. The company's strategic positioning emphasizes innovation in implant technology, aiming for high standards of surgical precision and patient recovery outcomes.
- Ticker
- Fr. MED
- Sector
- Health
- Primary listing
- XSWX
- Employees
- 1,428
- Headquarters
- Basel, Switzerland
- Website
- www.medartis.com
MED Metrics
BasicAdvanced
CHF 1.1B
71.22
CHF 1.20
1.17
-
Price and volume
Market cap
CHF 1.1B
Beta
1.17
52-week high
CHF 97.50
52-week low
CHF 70.60
Average daily volume
15K
Financial strength
Current ratio
3.361
Quick ratio
1.617
Long term debt to equity
0.698
Total debt to equity
0.735
Interest coverage (TTM)
2.58%
Profitability
EBITDA (TTM)
29.078
Gross margin (TTM)
77.48%
Net profit margin (TTM)
4.86%
Operating margin (TTM)
2.90%
Effective tax rate (TTM)
31.10%
Revenue per employee (TTM)
CHF 220,000
Management effectiveness
Return on assets (TTM)
1.03%
Return on equity (TTM)
5.75%
Valuation
Price to earnings (TTM)
71.224
Price to revenue (TTM)
3.457
Price to book
3.78
Price to tangible book (TTM)
30.05
Price to free cash flow (TTM)
-894.325
Free cash flow yield (TTM)
-0.11%
Free cash flow per share (TTM)
-0.095
Growth
Revenue change (TTM)
29.92%
Earnings per share change (TTM)
-2,486.22%
3-year revenue growth (CAGR)
15.81%
3-year earnings per share growth (CAGR)
29.85%
What the Analysts think about MED
Analyst ratings (Buy, Hold, Sell) for Medartis Holding AG stock.
Analyst projections of the future price of Medartis Holding AG stock.
Bulls say / Bears say
H1 organic core sales grew 17%, prompting Medartis to raise its 2026 growth forecast to 17%–19% from 16%–18%. That points to strong demand and continued share gains in key markets. (Medartis)
US organic core sales rose 27.4% in H1, and Medartis raised its 2026 target for US TOUCH thumb-prosthesis procedures to 1,800 from 1,200. Faster adoption could give the company room to grow in a large market where it is still expanding its presence. (Medartis)
Core EBITDA rose to CHF 28.8 million from CHF 21.8 million, while the core EBITDA margin improved to 18.0%. The return to H1 net profit suggests that sales growth is beginning to translate into better earnings. (Medartis)
Free cash flow was negative CHF 10.1 million in H1, and cash fell to CHF 25.8 million from CHF 33.0 million at year-end 2025. Capacity spending, acquisitions and earn-out payments mean strong sales have yet to translate into cash generation. (Medartis)
The shares carried a trailing P/E of about 76.7 times in late August, against a peer average of 27.8 times, according to Simply Wall St. Such a high multiple leaves the price vulnerable if growth or margins disappoint. (Simply Wall St)
Currency and US tariffs remain a drag: Medartis said dollar weakness reduced US sales growth in Swiss francs, while tariff costs still affected H1 results. These headwinds could limit reported growth and profitability even if underlying demand stays strong. (Medartis)
Data summarised monthly by Lightyear AI. Last updated on 11 Oct 2026.
MED Financial Performance
Revenues and expenses
MED Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing MED
AllUSDEURGBP
Fund name | Fund size | Fr. MED weighting |
|---|---|---|
Vanguard FTSE Global All-cap$VALU | $199M | 0.00% |
Vanguard FTSE Global All-cap€VGLA | €171M | 0.00% |
Vanguard FTSE Global All-cap£VALL | £147M | 0.00% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.